Lyra Therapeutics, Inc.LYRANASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank38
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P38
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -11.70% |
| Q2 2025 | 25.47% |
| Q1 2025 | 22.11% |
| Q4 2024 | 30.03% |
| Q3 2024 | 18.81% |
| Q2 2024 | 11.02% |
| Q1 2024 | -17.82% |
| Q4 2023 | -35.03% |
| Q3 2023 | 1.18% |
| Q2 2023 | 9.89% |
| Q1 2023 | -30.30% |
| Q4 2022 | -12.15% |
| Q3 2022 | -28.05% |
| Q2 2022 | 28.85% |
| Q1 2022 | -5.38% |
| Q4 2021 | -9.53% |
| Q3 2021 | -405.06% |
| Q2 2021 | 144.55% |
| Q1 2021 | -29.35% |
| Q4 2020 | -55.24% |
| Q3 2020 | 49.45% |
| Q2 2020 | -86.16% |
| Q1 2020 | -2.53% |
| Q4 2019 | -2.38% |
| Q3 2019 | -27.40% |
| Q2 2019 | 0.03% |
| Q1 2019 | 0.00% |